Determining the effect of local use of injectable vancomycin in preventing exit site infection in children with peritoneal dialysis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240106060632N1

Enrollment

Registered

2024-08-12

Start date

2024-08-21

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exit site infection of peritoneal dialysis. Generalized (acute) peritonitis

Interventions

Intervention group: Intervention group: Patients in the topical vancomycin intervention group will receive 1 cc of vancomycin with a concentration of 100 mg/ml or 200 mg/ml based on Scourefont.

Eligibility

Sex/Gender

All

Age

2 Months to 18 Years

Inclusion criteria

Inclusion criteria: Receiving Peritoneal Dialysis 2 Months to 18 years old Not having a history of Vancomycin Allergy Absence of Underlying Dermatologic Diseases based on initial clinical evaluation Informed Consent Not Receiving Systemic Antibiotics in last month

Exclusion criteria

Exclusion criteria: Sensitivity to Vancomycin Younger than 2 Month old

Design outcomes

Primary

Measure	Time frame
Peritoneal Dialysis exit site infection. Timepoint: 1 Week , 3 Month , 6 Month. Method of measurement: Physical exam.	—

Secondary

Measure	Time frame
Infectious Peritonitis. Timepoint: 3 Month and 6 Month. Method of measurement: Clinical signs and peritoneal fluid culture.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Saberi

Mashhad University of Medical Sciences

f.saberi.73@gmail.com+98 51 3878 4051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026